Learn how utilizing a site network can improve clinical trial efficiency and scalability, data quality, patient access and recruitment, resource optimization, and regulatory compliance. Discover more about speeding clinical trials with the use of site networks ..read more

Listen now as industry experts reveal the results of a recent rheumatoid arthritis (RA) survey and one patient shares her journey from onset to treatment. Don’t miss this inside look at the forces shaping RA clinical research ..read more

Summer Colling speaks with Emma Wille about the Psychedelic Symposium at the University of Wisconsin-Madison and what the future of psychedelic therapeutics could look like ..read more

Audio roundup of selected biopharma industry content from Scrip over the business week ended 6 December 2024. In this episode: Zepbound bests Wegovy; Novartis and PTC’s Huntingdon’s deal; Vabysmo hopes to ride new listing, data in Asia; Leo Pharma gains momentum; and Immunic’s hopes for MS drug. https://insights.citeline.com/scrip/podcasts/scrips-five-must-know-things/quick-listen-scrips-five-must-know-things-FU2EL35AAJBGLIK4EL7KVQRAGU/ Playlist: soundcloud.com/citelinesounds/sets/scrips-five-must-know-things ..read more

In this episode of the In Vivo podcast, Peter Flynn, CEO of Arialys Therapeutics, discusses the exciting field of autoimmune neuropsychiatry and the company’s monoclonal antibody, which it is investigating for the treatment of a rare condition called anti-NMDA receptor encephalitis and potentially other indications ..read more

Pink Sheet reporter and editors discuss potential threats to the COVID-19 vaccine pediatric indications under the Trump Administration (:24), the DOGE commission’s search for spending cuts and its impact on the FDA (12:52), as well as a new 340B rebate pricing model that some pharma companies are implementing to contain the program’s costs (22:52). More On These Topics From The Pink Sheet Pediatric COVID Shots, Still Under EUA, Would Be Vulnerable In Anti-Vax HHS: https://insights.citeline.com/pink-sheet/vaccines/pediatric-covid-shots-still-under-eua-would-be-vulnerable-in-anti-vax-hhs-UWJRLYQ ..read more

Emma and Summer meet with oncology analysts Neha Anand and David Dahan, to discuss an emerging class of drugs: bispecific antibodies ..read more

In this episode of the In Vivo podcast, Michelle Werner, CEO of Alltrna, discusses using tRNA as a therapeutic modality for rare diseases, including those stemming from nonsense mutations ..read more

Biopharma is evolving through collaboration, early-phase deal-making and innovation in precision medicine and AI. At BIO-Europe, Norstella's subject matter experts explored key trends shaping the industry, from market access strategies to sustaining growth through partnerships. In this episode, Izabela Chmielewska, Kevin Grogan, and Natasha Choukkar discuss takeaways – from advancing personalized treatments to tackling the patent cliff – highlighting how Norstella empowers organizations to navigate complexity and drive innovation ..read more

Audio roundup of selected biopharma industry content from Scrip over the business week ended 29 November 2024. In this episode: Marks on Trump’s threat to FDA; Amgen’s Phase II MariTide data lack clarity; Roche’s Poseida buyout; Roche’s CMO on his biotech lessons; and what Trump 2.0 might mean for India. https://insights.citeline.com/scrip/podcasts/quick-listen-scrips-five-must-know-things-GIXQTTFOANHRLAWTJEMLY6Z2LI/ Playlist: soundcloud.com/citelinesounds/sets/scrips-five-must-know-things ..read more